Novel neurotensin analog blocks the initiation and expression of nicotine-induced locomotor sensitization.
Neurotensin is a tridecapeptide that participates in regulation of dopaminergic pathways implicated in nicotine addiction. Previously, we showed that one of our brain-penetrating neurotensin analogs, NT69L, blocks nicotine-induced locomotor sensitization. The present work demonstrates that NT69L blocks both the initiation and the expression of sensitization. In addition chronic NT69L administration blocked the acute effects of nicotine on norepinephrine and serotonin in prefrontal cortex.
Fredrickson
Paul
P
Nicotine Dependence Center, Mayo Foundation for Medical Education and Research, and Mayo Clinic Jacksonville, 32224, Jacksonville, FL, USA.
Boules
Mona
M
Yerbury
Sally
S
Richelson
Elliott
E
D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D004298:Dopamine / Q000032:analysis / Q000378:metabolism; D005731:Ganglionic Stimulants / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D009496:Neurotensin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology; D009638:Norepinephrine / Q000032:analysis / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000032:analysis / Q000378:metabolism; D013997:Time Factors
D005731:Ganglionic Stimulants; D010446:Peptide Fragments; C407426:neurotensin 69L; D012701:Serotonin; D009496:Neurotensin; D009538:Nicotine; D004298:Dopamine; D009638:Norepinephrine